Drug profile · INN
anakinra
KINERET
anakinra (KINERET) is a interleukin-1 receptor antagonist. Associated with Swedish Orphan Biovitrum Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — anakinra
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 18
- Data quality
- 0.84
Quick answer
anakinra (KINERET) is a interleukin-1 receptor antagonist. Associated with Swedish Orphan Biovitrum Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin-1 receptor antagonist
Primary target: Interleukin-1 receptor type 1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is anakinra?
anakinra (KINERET) is a interleukin-1 receptor antagonist. Associated with Swedish Orphan Biovitrum Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for anakinra?
KINERET is a marketed brand name for anakinra. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of anakinra?
anakinra has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.